Reuters: Global Markets: Oncolytics lung cancer drug shrinks tumors in 92 percent of patients in trial

Reuters: Global Markets Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Design-Led Engineering Sourcebits - When your Mobile App has to be absolutely developed right. We've built more than 20 apps that have cracked the Top 10 in the App Store. From our sponsors

Oncolytics lung cancer drug shrinks tumors in 92 percent of patients in trial Sep 9th 2013, 12:17 Mon Sep 9, 2013 8:17am EDT (Reuters) - Oncolytics Biotech Inc said its cancer drug Reolysin reduced the size of tumors in 92 percent of lung cancer patients in a mid-stage trial. The company's shares rose as much as 22 percent to $3.22 in trading before the bell. The drug was tested on patients suffering from advanced squamous cell carcinoma of the lung. It was used intravenously in combination with chemotherapy drugs carboplatin and paclitaxel. "Squamous cell carcinoma of the lung is notoriously difficult to treat, and these results support further investigation of Reolysin in randomized clinical trials for this indication," Chief Executive Brad Thompson said in a statement on Monday. Squamous cell carcinomas account for 25 percent to 30 percent of all lung cancers, according to the American Cancer Society. Final progression-free survival and safety data for the study will be reported later in the year, the Calgary-based company said.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions